drugset / Trial / NCT04723524
Jinhua Qinggan Granules in the Treatment of COVID-19
Phase 2
Completed
402 enrolled
University of Karachi
Dow University Hospital, Mission Rd, Gulzar-e-Hijri, Scheme 33, Karachi. Tel: (92-21) 38771111 · collabDr. Ruth K.M. Pfau Civil Hospital, Karachi · collabIndus Hospital and Health Network · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The clinical trial is designed to be randomized, double blind, placebo controlled, to evaluate the effectiveness and safety of Jinhua Qinggan granules (JHQG) on mild-category patients of COVID-19 in Pakistani population with the age limit of 18-75 years, at10th day comprehensive follow-up. The informed consent form must be signed by the subjects before their participation in the trial.
Timeline
- Start
- 2020-09-22
- Primary completion
- 2021-08-23
- Completion
- 2021-08-23
Publications
- Background Zhang Q, Cao F, Wang Y, Xu X, Sun Y, Li J, Qi X, Sun S, Ji G, Song B. The efficacy and safety of Jinhua Qinggan granule (JHQG) in the treatment of coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis. Medicine (Baltimore). 2020 Jun 12;99(24):e20531. doi: 10.1097/MD.0000000000020531.
- Shah MR, Fatima S, Khan SN, Ullah S, Himani G, Wan K, Lin T, Lau JYN, Liu Q, Lam DSC. Jinhua Qinggan granules for non-hospitalized COVID-19 patients: A double-blind, placebo-controlled, and randomized controlled trial. Front Med (Lausanne). 2022 Aug 1;9:928468. doi: 10.3389/fmed.2022.928468. eCollection 2022.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Jinhua Qinggan (JHQG) Granules | Traditional medicine (herbal / TCM) | 5 g | Oral |